RDY News & Events

Dr. Reddy's Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy's is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance, NOC, received from Health Canada on April 28th, 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy's readiness to ensure patient access following approval.

Dr. Reddy's Laboratories announced that it has received a Notice of Compliance, NOC, from Health Canada for its generic Semaglutide Injection. Dr. Reddy's becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada, ahead of Health Canada's review target date. The market authorization covers the 2 mg / pen and 4 mg / pen. With launch preparations underway, Dr. Reddy's is well-positioned to bring this important treatment option available to Canadian patients.